ELI LILLY & Co
LLYNYSE · SIC 2834
$1,179.11
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +50.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1T
Enterprise Value
$1.1T
P/E
41.9
P/S
14.6
P/B
33.9
EV/EBITDA
—
PEG
0.9
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$72.2B
Net Income (TTM)
$25.3B
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
35.0%
ROE
81.0%
ROIC
—
Debt / Equity
1.4
Net Cash
-$38.1B
Return 1Y
+55.9%
Company profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
- CEO
- David A. Ricks
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 39,000
- Headquarters
- Indiana
- Website
- lilly.com
Management & directors
- Yuffa IlyaEVP&Pres, LLY USA&Global Capab
- Dozier EricEVP, Chief People Officer
- Brown Adrienne SEVP, President LLY Imm
- Custer Kenneth L.EVP & President, Card Met Hlth
- Montarce LucasEVP & CFO
- Zakrowski Donald ASVP, Finance, & CAO
- Hakim AnatEVP, GC & Secretary
- Hernandez EdgardoEVP & Pres., Mfg. Operations
- Jonsson PatrikEVP & President, LLY Int'l
- Rau DiogoEVP & CIDO
- Ricks David APresident, Chair, and CEO
- Skovronsky DanielEVP, CSO & Pres. LRL & LLY Imm
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
LLY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$19.8B↑ +55.5%
Diluted EPS$8.26↑ +169.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.5B | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | $6.2B | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Diluted EPS | $6.79 | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Operating cash flow | $6.5B | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.3B | $11.4B | $13.5B | $12.7B | $15.6B | $17.6B | $19.3B | $19.8B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $3.0B | $970.3M | $4.4B | $2.8B | $5.7B | $5.6B | $6.6B | $7.4B |
| Diluted EPS | $3.28 | $1.07 | $4.88 | $3.06 | $6.29 | $6.21 | $7.39 | $8.26 |
| Operating cash flow | $1.5B | $3.7B | $2.5B | $1.7B | $3.1B | $8.8B | $3.2B | $5.3B |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 26.3% | 8.5% | 32.6% | 21.7% | 36.4% | 31.7% | 34.4% | 37.4% |
Company news
Jul 20, 2026
- 11m agoScribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchasefinance.yahoo.com
- 43m agoSector Update: Healthcare Stocks Fall Late Afternoonfinance.yahoo.com
- 1h agoReading Between The Lines Of JNJ Stock's Latest Calltrefis.com
- 1h agoNow That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?fool.com
- 2h agoEli Lilly Stock And The Price Of Confidencetrefis.com
- 6h agoDoes EU Approval of Wegovy Pill Change NVO's Competitive Story?finance.yahoo.com
- 7h agoEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on Itfinance.yahoo.com
- 7h agoShould You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?finance.yahoo.com
- 7h agoATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upsidestocktwits.com
- 10h ago‘Wild West’ of Untested Peptides Has Americans Paying in Crypto to Get Their Fixfinance.yahoo.com
- 14h agoATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholdersstocktwits.com
- 16h agoWhy Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?stocktwits.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | LUCIANO JUAN R | Award | 14 | $1,129.35 | $15,916.72 | filing |
| 2026-06-15 | Alvarez Ralph | Award | 11 | $1,129.35 | $12,416.64 | filing |
| 2026-06-15 | Fyrwald J Erik | Award | 9 | $1,129.35 | $9,916.71 | filing |
| 2026-06-15 | Sulzberger Gabrielle | Award | 4 | $1,129.35 | $4,958.30 | filing |
| 2026-06-10 | Yuffa Ilya· EVP&Pres, LLY USA&Global Capab | Sale | 2,500 | $1,150.77 | $2.9M | filing |
| 2026-05-18 | LUCIANO JUAN R | Award | 16 | $988.09 | $15,917.14 | filing |
| 2026-05-18 | Alvarez Ralph | Award | 13 | $988.09 | $12,416.34 | filing |
| 2026-05-18 | Fyrwald J Erik | Award | 10 | $988.09 | $9,916.47 | filing |
| 2026-05-18 | Sulzberger Gabrielle | Award | 5 | $988.09 | $4,958.24 | filing |
| 2026-05-06 | LILLY ENDOWMENT INC | Sale | 13,620 | $995.23 | $13.6M | filing |
| 2026-05-06 | LILLY ENDOWMENT INC | Sale | 2,208 | $996.18 | $2.2M | filing |
| 2026-04-20 | LUCIANO JUAN R | Award | 17 | $919.90 | $15,917.03 | filing |
| 2026-04-20 | Alvarez Ralph | Award | 14 | $919.90 | $12,416.81 | filing |
| 2026-04-20 | Fyrwald J Erik | Award | 11 | $919.90 | $9,916.52 | filing |
| 2026-04-20 | Sulzberger Gabrielle | Award | 5 | $919.90 | $4,958.26 | filing |
| 2026-03-16 | LUCIANO JUAN R | Award | 16 | $989.12 | $15,916.92 | filing |
| 2026-03-16 | Alvarez Ralph | Award | 13 | $989.12 | $12,416.42 | filing |
| 2026-03-16 | Fyrwald J Erik | Award | 10 | $989.12 | $9,916.92 | filing |
| 2026-03-16 | Greene-Sulzberger Gabrielle | Award | 5 | $989.12 | $4,958.46 | filing |
| 2026-02-19 | Dozier Eric· EVP, Chief People Officer | Gift | 481 | $0.00 | $0.00 | filing |
| 2026-02-17 | LUCIANO JUAN R | Award | 15 | $1,036.05 | $15,916.84 | filing |
| 2026-02-17 | Alvarez Ralph | Award | 12 | $1,036.05 | $12,417.06 | filing |
| 2026-02-17 | Fyrwald J Erik | Award | 10 | $1,036.05 | $9,917.07 | filing |
| 2026-02-17 | Greene-Sulzberger Gabrielle | Award | 5 | $1,036.05 | $4,958.54 | filing |
| 2026-02-16 | Brown Adrienne S· EVP, President LLY Imm | Tax withholding | 170 | $1,040.00 | $176,764.64 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.